Roberts Wealth Advisors LLC Purchases New Stake in Danaher Corporation $DHR

Roberts Wealth Advisors LLC purchased a new stake in Danaher Corporation (NYSE:DHR) during the 3rd quarter, Holdings Channel.com reports. The institutional investor purchased 8,739 shares of the conglomerate’s stock, valued at approximately $1,936,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Marquette Asset Management LLC boosted its stake in shares of Danaher by 192.1% during the 3rd quarter. Marquette Asset Management LLC now owns 111 shares of the conglomerate’s stock worth $25,000 after acquiring an additional 73 shares in the last quarter. N.E.W. Advisory Services LLC acquired a new position in shares of Danaher in the 2nd quarter worth $25,000. Main Street Group LTD acquired a new position in shares of Danaher in the 1st quarter worth $25,000. Field & Main Bank acquired a new stake in shares of Danaher during the second quarter worth $29,000. Finally, Evolution Wealth Management Inc. raised its position in shares of Danaher by 208.0% during the first quarter. Evolution Wealth Management Inc. now owns 154 shares of the conglomerate’s stock worth $29,000 after purchasing an additional 104 shares during the period. Institutional investors and hedge funds own 79.05% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on DHR shares. Wells Fargo & Company reduced their target price on Danaher from $212.00 to $195.00 and set an “equal weight” rating for the company in a report on Wednesday, July 22nd. Evercore reissued an “outperform” rating and issued a $230.00 price target on shares of Danaher in a research note on Monday, July 6th. UBS Group assumed coverage on Danaher in a research note on Wednesday, September 9th. They issued a “buy” rating and a $250.00 price target on the stock. Morgan Stanley boosted their price objective on Danaher from $220.00 to $240.00 and gave the stock an “overweight” rating in a report on Monday. Finally, Royal Bank Of Canada upped their price objective on shares of Danaher from $215.00 to $250.00 and gave the company an “outperform” rating in a research note on Monday, October 5th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $235.41.

Danaher Trading Up 0.9%

Danaher stock opened at $223.30 on Wednesday. Danaher Corporation has a 52 week low of $160.93 and a 52 week high of $242.80. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65. The firm has a market capitalization of $156.98 billion, a price-to-earnings ratio of 39.66, a P/E/G ratio of 2.78 and a beta of 0.76. The company has a 50 day moving average price of $212.41 and a 200 day moving average price of $195.13.

Danaher (NYSE:DHR) last announced its earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The company had revenue of $6.26 billion for the quarter, compared to the consensus estimate of $6.12 billion. During the same period in the previous year, the business earned $0.77 EPS. The company’s revenue was up 5.5% on a year-over-year basis. Research analysts forecast that Danaher Corporation will post 8.53 EPS for the current year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a $0.40 dividend. This represents a $1.60 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend is Wednesday, September 30th. Danaher’s dividend payout ratio (DPR) is 28.42%.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.